ATR is a critical dependency gene for uveal melanoma
- 1Department of Radiation Oncology, Vanderbilt University Medical Center
Abstract
GNAQ, GNA11, CYSLTR2, and PLCB4 are well-characterized oncogenic drivers of uveal melanoma (UM). The oncogenic stress induced by these mutations creates a reliance on specific dependency genes that support tumor cell proliferation and survival. However, the genes that broadly contribute to UM cell fitness remain incompletely defined. Using the Dependency Map (DepMap), we identified ATR (HGNC:882; ATR checkpoint kinase) as a key regulator of UM cell fitness. Pharmacologic inhibition of ATR with the selective inhibitor VE-822 in 92.1, MEL270 and MP38 cells, established models of low-risk, intermediate-risk, and high-risk UM respectively, resulted in DNA double-strand break formation, micronuclei accumulation, and a marked reduction in colony and spheroid formation. RNA sequencing followed by pathway enrichment analysis was performed to characterize the transcriptional response to ATR inhibition. Transcriptomic profiles from cell lines support the hypothesis that successful completion of S phase and mitotic progression are critical determinants of the response of UM cells to ATR inhibition. Further support for the hypothesis that mitotic progression is a key factor for ATR-inhibited cells was obtained by treating with VE-822, paclitaxel, or the combination. Combining ATR and microtubule inhibition produced significant synergy in the UM models. Collectively, these findings identify ATR as a potential therapeutic vulnerability in uveal melanoma.
Related
- Uveal melanoma: In the era of new treatments
- PRAME predicting outcome in uveal melanoma
- 114 CXCL6 emerges as a novel marker of an immunosuppressive, angiogenic, and epithelial-mesenchymal transition (EMT)-enriched metastatic program in uveal melanoma (UM)
- The conformation-selective PI3Kδ inhibitor roginolisib in patients with advanced or metastatic cancer, including metastatic uveal melanoma: first-in-human clinical trial
- BAP1 loss and PRAME expression converge to remodel the tumor-immune ecosystem during uveal melanoma progression
BibTeX
@article{traver2026critical,
title = {{ATR is a critical dependency gene for uveal melanoma}},
author = {Geri Traver and Kaely Tornek and Michael L. Freeman},
journal = {Scientific Reports},
year = {2026},
month = aug,
doi = {10.1038/s41598-026-65725-9},
url = {https://doi.org/10.1038/s41598-026-65725-9},
note = {CC BY},
}
RIS
TY - JOUR
TI - ATR is a critical dependency gene for uveal melanoma
AU - Geri Traver
AU - Kaely Tornek
AU - Michael L. Freeman
PY - 2026
DA - 2026/08/01
JO - Scientific Reports
DO - 10.1038/s41598-026-65725-9
UR - https://doi.org/10.1038/s41598-026-65725-9
AB - GNAQ, GNA11, CYSLTR2, and PLCB4 are well-characterized oncogenic drivers of uveal melanoma (UM). The oncogenic stress induced by these mutations creates a reliance on specific dependency genes that support tumor cell proliferation and survival. However, the genes that broadly contribute to UM cell fitness remain incompletely defined. Using the Dependency Map (DepMap), we identified ATR (HGNC:882; ATR checkpoint kinase) as a key regulator of UM cell fitness. Pharmacologic inhibition of ATR with the selective inhibitor VE-822 in 92.1, MEL270 and MP38 cells, established models of low-risk, intermediate-risk, and high-risk UM respectively, resulted in DNA double-strand break formation, micronuclei accumulation, and a marked reduction in colony and spheroid formation. RNA sequencing followed by pathway enrichment analysis was performed to characterize the transcriptional response to ATR inhibition. Transcriptomic profiles from cell lines support the hypothesis that successful completion of S phase and mitotic progression are critical determinants of the response of UM cells to ATR inhibition. Further support for the hypothesis that mitotic progression is a key factor for ATR-inhibited cells was obtained by treating with VE-822, paclitaxel, or the combination. Combining ATR and microtubule inhibition produced significant synergy in the UM models. Collectively, these findings identify ATR as a potential therapeutic vulnerability in uveal melanoma.
SN - 2045-2322
ER -